We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Journal Scan / Research · June 01, 2020

Earlier Development of IRAEs Is Associated With Poor Clinical Outcome in mRCC Patients Treated With Nivolumab

Clinical Genitourinary Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Genitourinary Cancer
Correlation Between Immuno-Related Adverse Events (IRAEs) Occurrence and Clinical Outcome in Metastatic Renal Cell Carcinoma (mRCC) Patients Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study
Clin Genitourin Cancer 2020 May 20;[EPub Ahead of Print], VM Giuseppa, P Stefania, V Marta, et al

Further Reading